Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma-Reference-Cited by-同舟云学术

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

Published:2017-01-19 Issue:3 Volume:6 Page:e1283462
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Simeone Ester¹,Grimaldi Antonio Maria¹,Festino Lucia¹,Giannarelli Diana²,Vanella Vito¹,Palla Marco¹,Curvietto Marcello¹,Esposito Assunta¹,Palmieri Giuseppe³^ORCID,Mozzillo Nicola³,Ascierto Paolo Antonio¹^ORCID

Affiliation:

1. Melanoma, Cancer Immunotherapy and Innovative Therapies O.U., Istituto Nazionale Tumori Fondazione “G. Pascale”, Napoli, Italy

2. Regina Elena National Cancer Institute, Rome, Italy

3. Unit of Melanoma and Sarcoma Surgery, Istituto Nazionale Tumori Fondazione, Napoli, Italy

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1283462

Reference22 articles.

1. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

2. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials

3. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

4. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

5. Do BRAF inhibitors select for populations with different disease progression kinetics?

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-08-21

2. System analysis based on the pyroptosis-related genes identifes GSDMD as a novel therapy target for skin cutaneous melanoma;Journal of Translational Medicine;2023-11-10

3. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?;Cancer and Metastasis Reviews;2023-04-06

4. Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned;Current Oncology Reports;2023-03-30

5. Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma;Cancer Immunology Research;2023-02-23